NAD+ and Cancer: What the Evidence Actually Says

This ongoing series explores the supplement trends people are talking about now, and the science behind them. We’ll cover emerging ingredients, new research, social media buzz, and occasional adjacent health topics that help explain where wellness is headed.

NAD+ sits at the center of two research programs that want opposite things...

Longevity labs want to raise it. Oncology labs have spent two decades trying to drain it out of tumors. Both camps have good reasons, and that tension is exactly why the cancer question resists a clean answer.

The starting fact is uncomfortable. Every cell you have runs on NAD+, and so does every cancer cell. NAD+ is the cofactor behind the redox reactions of glycolysis, oxidative phosphorylation, fatty acid oxidation, and the TCA cycle. 

It also fuels two enzyme families cancer leans on heavily: PARPs, which repair DNA damage, and sirtuins, which manage stress and gene expression. Because tumors reprogram their metabolism and divide fast, they burn through NAD+ and have to keep remaking it. Most of that remaking runs through one salvage enzyme, NAMPT, which is overexpressed across a long list of cancers.

So there are two ways to point NAD+ at cancer, and researchers have chased both.

Draining NAD+: the drug side

If tumors depend on NAD+, starve them of it. That logic drove a generation of NAMPT inhibitors. FK866 and CHS828 killed cancer cells at nanomolar concentrations in the lab and shrank tumors in mice. The problem showed up in people. 

The earliest versions of these drugs ran into trouble in their first rounds of human testing. At the doses needed to work, they caused serious side effects, including dangerously low levels of platelets (the blood cells that help you stop bleeding) and stomach and digestive problems. On top of that, the drugs rarely shrank tumors in a measurable way. 

Together, those two problems were enough to shut down most of these early drug programs. A 2022 review by Navas and Carnero, which looked at whether targeting a cellular fuel called NAD could fight cancer, tells this story in detail.

Newer compounds are trying to widen the therapeutic window. KPT-9274, a dual PAK4-NAMPT inhibitor, moved through first-in-human testing in advanced solid tumors, sometimes paired with niacin to spare healthy tissue.

The depletion strategy isn't dead. But after twenty years, no NAD-lowering drug has become standard care, which tells you how narrow the margin is between hurting the tumor and hurting the patient.

Raising NAD+: the prevention side

The other direction is where supplements live, and here the flagship evidence is genuinely positive. Nicotinamide — a form of vitamin B3 — is a direct precursor to NAD+. When you take it as a supplement, your cells feed it through the same salvage pathway that cancer cells depend on, converting it into NAD+ via NAMPT.

The idea is simple: if depleting NAD+ can kill a tumor, topping it up might help healthy cells protect themselves.

The standout study is a trial called ONTRAC. In 2015, Chen and colleagues ran a large, carefully designed experiment: they took 386 people who had healthy immune systems but a history of skin cancer (each had had at least two non-melanoma skin cancers in the previous five years) and split them at random into two groups. One group took nicotinamide at 500 mg twice a day for a year. The other group took a placebo, a dummy pill with no active ingredient. Splitting people randomly and comparing against a placebo is the gold standard for figuring out whether a treatment actually works.

The result: the vitamin group developed 23% fewer new skin cancers than the placebo group.

There's also a sensible reason this would work.

Nicotinamide helps skin cells repair the DNA damage caused by the sun's UV rays, and it counteracts the way UV exposure weakens the skin's local immune defenses. Both of those are plausible ways to head off sun-driven skin cancer.

Then things got more complicated. In 2023, Allen and colleagues repeated essentially the same experiment, but in a group at much higher risk: 158 organ-transplant recipients, who take drugs to suppress their immune systems (which leaves them far more prone to skin cancer). Same vitamin, same dose, same length of time. This time, the benefit disappeared. New skin cancers came in at almost exactly the same rate in both groups: 207 cases in the vitamin group versus 210 in the placebo group.

There’s some debate about why. Critics point out that the second trial was stopped early and didn’t enroll enough people to reliably detect a benefit, so a real effect could have been missed. But either way, the takeaway is the same: a result that looked solid in one group of people didn't automatically hold up in another.

The precursor contradiction

The NAD+ supplements most people actually take are what scientists call precursors: raw materials the body uses to build NAD+. 

The two common ones are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). When you look at the early cancer research on these, the findings openly contradict each other.

In 2022, Maric and colleagues designed a glowing chemical tag that let them watch where NR went inside living tissue. They found that an aggressive form of breast cancer, called triple-negative breast cancer, soaked up about four times more of the tag than milder cancer cells did. And in mice with weakened immune systems, a diet rich in NR caused that breast cancer to spread to the brain more.

A year later, Jiang and colleagues reported the exact opposite in the same type of cancer. Using mice carrying tumors grown from actual human patient samples, they found that boosting NAD+ with NMN reduced the cancer’s spread and helped the mice live about 15% longer. When they disabled a specific cellular pathway (a signaling chain involving a protein called SIRT1), the benefit vanished, which told them that pathway was responsible for the good effect.

So: the same aggressive cancer, opposite conclusions, both in mice. The two studies used different methods and setups, and neither one tells us what would happen in a human body. Taken together, the honest reading is that these supplements don't behave in a simply “protective” or “harmful” way. Their effects depend heavily on context.

The newest finding sharpens the caution. In 2026, Nakazzi and colleagues tested three NAD+ precursors in pancreatic cancer, one of the deadliest cancers there is. Across both lab dishes and mice, the precursors (with NMN having the strongest effect) shielded the cancer cells from three standard chemotherapy drugs.

The reason was clear, and not the kind of news you want. The supplements strengthened the cancer cells' internal energy machinery and reduced their stress levels, which helped the cells survive the very damage that chemotherapy is designed to inflict on them. In a disease where only about 13% of patients are alive five years after diagnosis, anything that weakens chemotherapy is a serious concern.

What the human evidence supports

Set against those alarming animal results, the human data is reassuring but thin.

No clinical study has shown that NAD+ precursors cause cancer in people.

More than seventy human trials indicate that NR and NMN reliably raise NAD+ and are generally well tolerated over weeks to months, with side effects that tend toward mild: nausea, digestive upset, headache, flushing, cramps. Decades of experience with niacin and nicotinamide add to that safety record.

The limits are worth naming plainly. Trials have been short, so nothing tells us what years of daily use does. And nearly all the worrying signals come from animals with active, aggressive tumors, not from healthy people taking a daily capsule.

So is it safe, and who’s it for?

The answer gets clear once you sort people by one question:

Is a tumor already in the picture?

For healthy adults with no cancer history, the read is “well tolerated, benefit unproven.” NR and NMN raise NAD+ reliably and cause mostly mild side effects over the weeks-to-months windows trials have tested. What no study can promise this group is long-term safety, because the long-term trials haven't been run, or long-term payoff, since the strongest lifespan test in mice came up empty. The tradeoff for a healthy person is low apparent short-term risk against an unproven reward.

For people with active cancer, the caution is real and specific. Every worrying result, the pancreatic chemoresistance and the breast-cancer metastasis signal alike, comes from models with a tumor already growing. 

The concern isn’t that a precursor plants cancer in a healthy body. It’s that it may feed cells that are already malignant, and may blunt chemotherapy that depends on oxidative stress and DNA damage to work. 

Anyone in active treatment, or with a personal or strong family history of cancer, has reason to hold off until an oncology team weighs in. The pancreatic-cancer authors went as far as calling for routine supplement screening in patients.

Where the evidence lands: NAD+ precursors look safe enough for healthy, short-term use and carry genuinely unknown long-term risk. The clearest reason to avoid them, for now, is active cancer or high cancer risk. And the single fact that decides which group you're in is whether a tumor is already in the room.

This article discusses cancer risk and supplement safety and is for general information, not medical advice. Anyone with a cancer history, active cancer, or ongoing treatment should talk with their oncology team before using NAD+ precursors.